Aligos Therapeutics Stock Alpha and Beta Analysis
| ALGS Stock | USD 9.12 0.54 5.59% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Aligos Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Aligos Therapeutics over a specified time horizon. Remember, high Aligos Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Aligos Therapeutics' market risk premium analysis include:
Beta 3.78 | Alpha (1.75) | Risk 7.36 | Sharpe Ratio (0.29) | Expected Return (2.10) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Aligos |
Aligos Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Aligos Therapeutics market risk premium is the additional return an investor will receive from holding Aligos Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Aligos Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Aligos Therapeutics' performance over market.| α | -1.75 | β | 3.78 |
Aligos Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Aligos Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Aligos Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Aligos Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Aligos Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Aligos Therapeutics shares will generate the highest return on investment. By understating and applying Aligos Therapeutics stock market price indicators, traders can identify Aligos Therapeutics position entry and exit signals to maximize returns.
Aligos Therapeutics Return and Market Media
The median price of Aligos Therapeutics for the period between Mon, Dec 30, 2024 and Sun, Mar 30, 2025 is 23.74 with a coefficient of variation of 45.29. The daily time series for the period is distributed with a sample standard deviation of 10.91, arithmetic mean of 24.08, and mean deviation of 9.26. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Aligos Therapeutics Announces 105 Million Private Placement Financing | 02/12/2025 |
2 | Acquisition by Quan Lucinda Y. of 48000 shares of Aligos Therapeutics at 0.84 subject to Rule 16b-3 | 02/18/2025 |
3 | Acquisition by Blatt Lawrence of 965435 shares of Aligos Therapeutics at 1.13 subject to Rule 16b-3 | 02/21/2025 |
4 | UniQure Reports Q4 Loss, Misses Revenue Estimates | 02/27/2025 |
5 | Acquisition by Calhoun Lesley Ann of 47271 shares of Aligos Therapeutics at 16.87 subject to Rule 16b-3 | 02/28/2025 |
6 | Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025 | 03/03/2025 |
7 | Acquisition by Blatt Lawrence of 140103 shares of Aligos Therapeutics at 16.87 subject to Rule 16b-3 | 03/04/2025 |
8 | Acquisition by Symons Julian A. of 78750 shares of Aligos Therapeutics at 1.34 subject to Rule 16b-3 | 03/07/2025 |
9 | Aligos Therapeutics GAAP EPS of -13.08 misses by 10.58 | 03/10/2025 |
10 | Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 03/14/2025 |
11 | Aligos Therapeutics files to sell 6.25M shares of common stock for holders | 03/27/2025 |
About Aligos Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Aligos or other stocks. Alpha measures the amount that position in Aligos Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | |
| Current Ratio | 4.03 | 5.9 | 2.86 | 2.72 |
| Net Debt To EBITDA | 0.73 | 1.46 | 0.32 | 0.3 |
Aligos Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Aligos Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aligos Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Aligos Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Aligos Therapeutics. Please utilize our Beneish M Score to check the likelihood of Aligos Therapeutics' management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Aligos Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.